Feedback control platform for advancing the delivery of critical care intravenous medications

Automedics Medical Sytems develops and commercializes a new class of medical devices designed to improve the delivery and control of critical care drugs for hospitals. These products will integrate monitoring, diagnostic assay results and proprietary feedback control algorithms to optimize the delivery of critical care drugs to improve patient safety and drug efficacy while improving hospital efficiency. This proprietary platform is applicable to a range of critical care intravenous medications that are difficult to control in acute care patients including anticoagulants, electrolytes, sedatives, antihypertensives, and metabolic control.

Automedics' product platform has the potential to provide solutions to significant unmet clinical needs in the acute care setting including tighter integration of critical parameters in the ICU, better patient management (e.g., improved outcomes, shortened length of stay), reduced medical errors, and better utilization of nursing personnel.

The first product in development, the AutoHep System, will address the critical issue of appropriate dosing and titration of the widely used anticoagulant, heparin. This System will address a very important clinical need to maintain patients in the correct therapeutic range, which will avert potential dosing errors, increase patient safety, and improve clinical outcomes. Automedics plans to have the AutoHep System in the marketplace in 36 months.

Following the successful trials of the AutoHep System, the Company plans on extending the platform to cover additional anticoagulant applications, sedation control with propofol, electrolyte control for potassium, antihypertensive control, and metabolic monitoring control with insulin. All of these applications will use the same platform with minor modifications. This opens up an entirely new, untapped market for dramatically improved control of potent critical-care medications in acute care.

The platform has been clinically tested in a pilot clinical trial with a research prototype that administered unfractionated heparin, a powerful anticoagulant, with outstanding results in keeping patients in the correct therapeutic range.